NCT02761642 2018-08-24
A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy
Hoffmann-La Roche
Phase 2 Completed
Clinical Trials
10 trialsNCT00776425 2017-07-02
A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies
Hoffmann-La Roche
Phase 4 Completed
NCT02767765 2017-04-04
A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy
Hoffmann-La Roche
Phase 3 Completed
NCT02554942 2016-11-02
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors
Hoffmann-La Roche
Phase 4 Completed
NCT02564094 2016-11-02
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies
Hoffmann-La Roche
Phase 4 Completed
NCT02608060 2016-11-02
A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B
Hoffmann-La Roche
Phase 4 Terminated
NCT02624141 2016-11-02
A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy
Hoffmann-La Roche
Phase 4 Terminated
NCT01809314 2016-08-19
An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy
Hoffmann-La Roche
Completed
NCT01168349 2015-10-02
An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)
Hoffmann-La Roche
Completed
NCT00628043 2009-09-18
Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients
Chugai Pharmaceutical
Phase 3 Completed